Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Recipient : Merit E. Cudkowicz, MD
Deal Size : Inapplicable
Deal Type : Inapplicable
HEALEY ALS Platform Trial - Regimen A Zilucoplan
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 18, 2020
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Recipient : Merit E. Cudkowicz, MD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology
Details : the study demonstrated that zilucoplan resulted in rapid, clinically meaningful, statistically significant, and sustained improvements in the primary and key secondary endpoints.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
February 18, 2020
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : UCB Pharma S.A
Deal Size : $2,300.0 million
Deal Type : Acquisition
Details : The transaction will enhance UCB’s potential to be a leader in myasthenia gravis by adding zilucoplan, currently in phase 3, to the UCB pipeline alongside rozanolixizumab.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
February 04, 2020
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : UCB Pharma S.A
Deal Size : $2,300.0 million
Deal Type : Acquisition
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial
Details : Zilucoplan was selected as one of the first clinical candidates to be evaluated in this platform trial for ALS led by the Sean M. Healey & AMG Center for ALS at Mass General.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
January 22, 2020
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 04, 2019
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 19, 2019
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 19, 2019
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 19, 2017
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 21, 2017
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 13, 2017
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable